Comparison of Aratana Therapeutics Inc. (PETX) and BiondVax Pharmaceuticals Ltd. (NASDAQ:BVXV)

Aratana Therapeutics Inc. (NASDAQ:PETX) and BiondVax Pharmaceuticals Ltd. (NASDAQ:BVXV), are influenced by contrast since they are both players in the Biotechnology. These factors are particularly influence the risk, analyst recommendations, profitability, institutional ownership, dividends, earnings and valuation of the two firms.

Valuation & Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Aratana Therapeutics Inc. 35.41M 5.03 14.72M -0.51 0.00
BiondVax Pharmaceuticals Ltd. N/A 0.00 N/A -2.30 0.00

Table 1 demonstrates Aratana Therapeutics Inc. and BiondVax Pharmaceuticals Ltd.’s gross revenue, earnings per share (EPS) and valuation.


Table 2 shows us Aratana Therapeutics Inc. and BiondVax Pharmaceuticals Ltd.’s return on equity, net margins and return on assets.

Net Margins Return on Equity Return on Assets
Aratana Therapeutics Inc. -41.57% -23% -16.1%
BiondVax Pharmaceuticals Ltd. 0.00% 0% 0%

Analyst Recommendations

Aratana Therapeutics Inc. and BiondVax Pharmaceuticals Ltd. Recommendations and Ratings are available in the next table.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Aratana Therapeutics Inc. 0 2 1 2.33
BiondVax Pharmaceuticals Ltd. 0 0 0 0.00

$5 is Aratana Therapeutics Inc.’s average target price while its potential upside is 36.61%.

Insider & Institutional Ownership

Institutional investors owned 69.1% of Aratana Therapeutics Inc. shares and 0% of BiondVax Pharmaceuticals Ltd. shares. About 2.5% of Aratana Therapeutics Inc.’s share are owned by insiders. Competitively, BiondVax Pharmaceuticals Ltd. has 22.93% of it’s share owned by insiders.


In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Aratana Therapeutics Inc. -3.6% -9.26% -39.09% -23.43% 3.08% -34.42%
BiondVax Pharmaceuticals Ltd. -2.76% -3.81% -16.86% -11.17% -19.57% 3.36%

For the past year Aratana Therapeutics Inc. has -34.42% weaker performance while BiondVax Pharmaceuticals Ltd. has 3.36% stronger performance.

Aratana Therapeutics, Inc., a pet therapeutics company, focuses on the licensing, development, and commercialization of therapeutics for dogs and cats in the United States and Belgium. Its product portfolio includes multiple therapeutics and therapeutic candidates in development consisting of small molecule pharmaceuticals and biologics. The company markets GALLIPRANT for the control of pain and inflammation associated with osteoarthritis in dogs; ENTYCE for appetite stimulation in dogs; and NOCITA, a post-operative anesthetic for cranial cruciate ligament surgery in dogs. The company is also developing AT-002 for evaluating capromorelin for weight management in cats with chronic kidney disease; AT-003, a bupivacaine liposome injectable suspension for post-operative pain management in cats; AT-006, an anti-viral for the treatment of feline herpes virus-induced ophthalmic conditions for cats; AT-016, an adipose-derived allogeneic stem cell therapeutic candidate for the treatment of osteoarthritis pain in dogs; and AT-018, an oral CRTH2 antagonist for the potential treatment of atopic dermatitis in dogs. In addition, the companyÂ’s licensed products include BLONTRESS, a canonized monoclonal antibody for the treatment of B-cell lymphoma in dogs; and TACTRESS, a canonized monoclonal antibody for the treatment of T-cell lymphoma in dogs, as well as AT-014, a novel her2/neu-directed cancer immunotherapy for the treatment of canine osteosarcoma for dogs. It has collaboration agreement with Elanco Animal Health, Inc. to develop, manufacture, and commercialize GRAPIPRANT products. Aratana Therapeutics, Inc. was founded in 2010 and is headquartered in Leawood, Kansas.

BiondVax Pharmaceuticals Ltd., a clinical stage biopharmaceutical company, focuses on developing and commercializing immunomodulation therapies for infectious diseases primarily in Israel. Its product candidate includes M-001, a synthetic peptide-based protein, which is in Phase II clinical development stage targeting seasonal and pandemic strains of the influenza virus. The company was founded in 2003 and is based in Ness Ziona, Israel.